RecruitingNCT04174742

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast Cancer

Sponsor

Wake Forest University Health Sciences

Enrollment

102 participants

Start Date

Dec 17, 2019

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Breast

Summary

The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will be carried out throughout the course of your chemotherapy treatment, which will be prescribed by your study doctor. Participation in this study will not affect your cancer treatment.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria7

Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
Age ≥ 18 years at the time of consent
Female
Histological or cytological confirmation of invasive breast cancer.
Planned to undergo adjuvant or neoadjuvant chemotherapy treatment for invasive breast cancer AND pegfilgrastim (or biosimilar substitution) treatment for neutropenic prophylaxis.
Ability to read and understand the English and/or Spanish language
As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study

Exclusion Criteria7

Subjects meeting any of the criteria below may not participate in the study:
Uncontrolled intercurrent illness/medical condition or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator
Have previously received chemotherapy or radiation other than the first cycle of the planned adjuvant or neoadjuvant chemotherapy as indicated in Inclusion #5
Taking chronic narcotics, as determined by treating physician
Diagnosis of distant metastatic breast cancer
Diagnosis of a chronic pain syndrome (e.g. fibromyalgia, severe osteoarthritis, etc.)
A baseline ESAS pain score of greater than 8.

Interventions

DRUGpegfilgrastim

It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.